Thiogenesis Therapeutics Past Earnings Performance
Past criteria checks 0/6
Thiogenesis Therapeutics's earnings have been declining at an average annual rate of -28.3%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-28.3%
Earnings growth rate
10.3%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | n/a |
| Return on equity | -98.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We're Keeping An Eye On Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
Nov 20
We Think Thiogenesis Therapeutics (CVE:TTI) Needs To Drive Business Growth Carefully
Jul 17Here's Why We're Not Too Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation
Aug 25We're Not Very Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
May 01Revenue & Expenses Breakdown
How Thiogenesis Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -4 | 1 | 3 |
| 30 Jun 24 | 0 | -4 | 1 | 4 |
| 31 Mar 24 | 0 | -5 | 1 | 4 |
| 31 Dec 23 | 0 | -5 | 1 | 4 |
| 30 Sep 23 | 0 | -3 | 1 | 2 |
| 30 Jun 23 | 0 | -3 | 1 | 2 |
| 31 Mar 23 | 0 | -3 | 1 | 2 |
| 31 Dec 22 | 0 | -4 | 1 | 1 |
| 30 Sep 22 | 0 | -4 | 1 | 1 |
| 30 Jun 22 | 0 | -3 | 1 | 1 |
| 31 Mar 22 | 0 | -3 | 0 | 1 |
| 31 Dec 21 | 0 | -1 | 0 | 1 |
Quality Earnings: TTI is currently unprofitable.
Growing Profit Margin: TTI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TTI is unprofitable, and losses have increased over the past 5 years at a rate of 28.3% per year.
Accelerating Growth: Unable to compare TTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: TTI has a negative Return on Equity (-98.61%), as it is currently unprofitable.